Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5471655 | 0.89 | NR3C1 (0.49) | NR3C1SIGMAR1HTR1ASLC6A4 | |
| SCHEMBL5478308 | 0.77 | TRPV1 (0.41) | NR3C1SIGMAR1 | |
| SCHEMBL5471002 | 0.75 | SIGMAR1 (0.50) | SIGMAR1HTR1ASLC6A4CHRM2CHRM4 | |
| SCHEMBL8019430 | 0.75 | SIGMAR1 (0.57) | SIGMAR1HTR1ACHRM2CHRM4ABCB1 | |
| SCHEMBL8811492 | 0.75 | SIGMAR1 (0.57) | SIGMAR1HTR1ACHRM2CHRM4ABCB1 | |
| SCHEMBL5477157 | 0.74 | NR3C1 (0.43) | NR3C1SIGMAR1HTR1ACHRM2CHRM4 | |
| SCHEMBL5474457 | 0.74 | UGT2B17 (0.46) | NR3C1 | |
| SCHEMBL5477879 | 0.74 | SIGMAR1 (0.60) | SIGMAR1HTR1ACHRM2CHRM4ABCB1 | |
| SCHEMBL15839894 | 0.73 | SIGMAR1 (0.57) | SIGMAR1CHRM2CHRM4ABCB1CHRM5 | |
| SCHEMBL15286771 | 0.73 | SIGMAR1 (0.57) | SIGMAR1CHRM2CHRM4ABCB1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | SCHERING AG (DE) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | TNF, CXCL8, MPO | NR3C1 83/4885SIGMAR1 1559/4885HTR1A 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.